Helix BioPharma Corp. (OTCMKTS:HBPCF – Get Free Report)’s share price shot up 17.9% on Thursday . The stock traded as high as $0.91 and last traded at $0.91. 200 shares traded hands during mid-day trading, an increase of 12% from the average session volume of 179 shares. The stock had previously closed at $0.78.
Helix BioPharma Price Performance
The business has a 50-day simple moving average of $0.41 and a 200-day simple moving average of $0.23. The company has a market cap of $223.05 million, a PE ratio of -45.50 and a beta of 0.01.
About Helix BioPharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.
Featured Stories
- Five stocks we like better than Helix BioPharma
- Market Cap Calculator: How to Calculate Market Cap
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- How to Choose Top Rated Stocks
- MarketBeat Week in Review – 9/9 – 9/13
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
